NASDAQ:OBSV - Obseva Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Obseva SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.45 +0.02 (+0.58 %) (As of 02/21/2020 02:25 PM ET) Add Compare Today's Range$3.38Now: $3.45▼$3.4750-Day Range$3.42MA: $3.71▼$4.4752-Week Range$2.37Now: $3.45▼$14.50Volume5,702 shsAverage Volume635,105 shsMarket Capitalization$156.91 millionP/E RatioN/ADividend YieldN/ABeta0.51 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBSV Previous Symbol CUSIPN/A CIK1685316 Webhttp://www.obseva.com/ Phone41-22-552-3840Debt Debt-to-Equity Ratio0.38 Current Ratio3.65 Quick Ratio3.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book1.07Profitability EPS (Most Recent Fiscal Year)($1.91) Net Income$-76,720,000.00 Net MarginsN/A Return on Equity-99.31% Return on Assets-75.70%Miscellaneous Employees43 Outstanding Shares45,480,000Market Cap$156.91 million Next Earnings Date3/3/2020 (Estimated) OptionableNot Optionable Receive OBSV News and Ratings via Email Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OBSV Rates by TradingView Obseva (NASDAQ:OBSV) Frequently Asked Questions What is Obseva's stock symbol? Obseva trades on the NASDAQ under the ticker symbol "OBSV." How were Obseva's earnings last quarter? Obseva SA (NASDAQ:OBSV) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.82) by $0.19. View Obseva's Earnings History. When is Obseva's next earnings date? Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Obseva. What price target have analysts set for OBSV? 4 brokerages have issued 12-month target prices for Obseva's stock. Their forecasts range from $4.00 to $40.00. On average, they anticipate Obseva's share price to reach $24.75 in the next year. This suggests a possible upside of 617.4% from the stock's current price. View Analyst Price Targets for Obseva. What is the consensus analysts' recommendation for Obseva? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva. What are Wall Street analysts saying about Obseva stock? Here are some recent quotes from research analysts about Obseva stock: 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (2/6/2020) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019) Has Obseva been receiving favorable news coverage? Press coverage about OBSV stock has trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obseva earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Obseva. Are investors shorting Obseva? Obseva saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,100,000 shares, an increase of 23.6% from the January 15th total of 890,200 shares. Based on an average trading volume of 955,200 shares, the short-interest ratio is currently 1.2 days. Currently, 5.1% of the company's stock are sold short. View Obseva's Current Options Chain. Who are some of Obseva's key competitors? Some companies that are related to Obseva include Urogen Pharma (URGN), Molecular Templates (MTEM), Phoenix Tree (IMAB), Atreca (BCEL), ZIOPHARM Oncology (ZIOP), XBiotech (XBIT), Clovis Oncology (CLVS), Kura Oncology (KURA), AC Immune (ACIU), Axovant Sciences (AXON), Crinetics Pharmaceuticals (CRNX), Ardelyx (ARDX), Puma Biotechnology (PBYI), Assembly Biosciences (ASMB) and MacroGenics (MGNX). What other stocks do shareholders of Obseva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Obseva investors own include Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX) and Crispr Therapeutics (CRSP). Who are Obseva's key executives? Obseva's management team includes the folowing people: Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)Mr. Timothy M. Adams, Chief Financial Officer (Age 59)Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)Mr. Mario Vincent Corso, Sr. Director of Investor RelationsDr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53) When did Obseva IPO? (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are Obseva's major shareholders? Obseva's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (1.45%), Point72 Asset Management L.P. (0.99%), Credit Suisse AG (0.76%), Renaissance Technologies LLC (0.49%), Pictet Asset Management Ltd. (0.33%) and Wedbush Securities Inc. (0.30%). Which major investors are selling Obseva stock? OBSV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Goldman Sachs Group Inc.. Which major investors are buying Obseva stock? OBSV stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Pictet Asset Management Ltd., Renaissance Technologies LLC, Wedbush Securities Inc., Ikarian Capital LLC, Zurcher Kantonalbank Zurich Cantonalbank, Geode Capital Management LLC and Acadian Asset Management LLC. How do I buy shares of Obseva? Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Obseva's stock price today? One share of OBSV stock can currently be purchased for approximately $3.45. How big of a company is Obseva? Obseva has a market capitalization of $156.91 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva. What is Obseva's official website? The official website for Obseva is http://www.obseva.com/. How can I contact Obseva? Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected] MarketBeat Community Rating for Obseva (NASDAQ OBSV)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 271 (Vote Outperform)Underperform Votes: 311 (Vote Underperform)Total Votes: 582MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: Pattern Day Trader
